251 related articles for article (PubMed ID: 25287756)
1. Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus.
Lutz M; Kapp M; Einsele H; Grigoleit GU; Mielke S
Clin Transplant; 2014 Dec; 28(12):1410-5. PubMed ID: 25287756
[TBL] [Abstract][Full Text] [Related]
2. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors.
Jedlickova Z; Burlakova I; Bug G; Baurmann H; Schwerdtfeger R; Schleuning M
Biol Blood Marrow Transplant; 2011 May; 17(5):657-63. PubMed ID: 20696263
[TBL] [Abstract][Full Text] [Related]
3. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
4. Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews.
Merkel EC; Mitchell SA; Lee SJ
Biol Blood Marrow Transplant; 2016 Apr; 22(4):752-758. PubMed ID: 26751003
[TBL] [Abstract][Full Text] [Related]
5. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
[TBL] [Abstract][Full Text] [Related]
6. Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis.
Mielke S; Lutz M; Schmidhuber J; Kapp M; Ditz D; Ammer J; Einsele H; Grigoleit GU; Holler E; Wolff D
Bone Marrow Transplant; 2014 Nov; 49(11):1412-8. PubMed ID: 25089598
[TBL] [Abstract][Full Text] [Related]
7. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease.
Akpek G; Lee SM; Anders V; Vogelsang GB
Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216
[TBL] [Abstract][Full Text] [Related]
8. Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation.
Herzberg PY; Heussner P; Mumm FH; Horak M; Hilgendorf I; von Harsdorf S; Hemmati P; Rieger K; Greinix H; Freund M; Lee SJ; Holler E; Wolff D
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1707-17. PubMed ID: 20541028
[TBL] [Abstract][Full Text] [Related]
9. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
Jurado M; Vallejo C; Pérez-Simón JA; Brunet S; Ferra C; Balsalobre P; Pérez-Oteyza J; Espigado I; Romero A; Caballero D; Sierra J; Ribera JM; Díez JL
Biol Blood Marrow Transplant; 2007 Jun; 13(6):701-6. PubMed ID: 17531780
[TBL] [Abstract][Full Text] [Related]
11. Symptoms, Cytokines, and Quality of Life in Patients Diagnosed with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation.
Lynch Kelly D; Lyon DE; Ameringer SA; Elswick RK
Oncol Nurs Forum; 2015 May; 42(3):265-75. PubMed ID: 25901378
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
[TBL] [Abstract][Full Text] [Related]
13. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
15. Female genital chronic graft-versus-host disease: importance of early diagnosis to avoid severe complications.
Hirsch P; Leclerc M; Rybojad M; Petropoulou AD; Robin M; Ribaud P; de la Tour RP; Cavelier-Balloy B; Socié G; Vexiau-Robert D
Transplantation; 2012 Jun; 93(12):1265-9. PubMed ID: 22466789
[TBL] [Abstract][Full Text] [Related]
16. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
[TBL] [Abstract][Full Text] [Related]
17. Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients.
Diaz MA; Vicent MG; Gonzalez ME; Verdeguer A; de la Rubia J; Bargay J; de Arriba F; Diez JL; Caballero D; Madero L; Brunet S;
Bone Marrow Transplant; 2004 Sep; 34(5):433-8. PubMed ID: 15273704
[TBL] [Abstract][Full Text] [Related]
18. Which questionnaires should we use to evaluate quality of life in patients with chronic graft-vs-host disease?
Perić Z; Desnica L; Duraković N; Ostojić A; Pulanić D; Serventi-Seiwerth R; Prenc E; Basak G; Vrhovac R; Pavletic SZ; Nemet D
Croat Med J; 2016 Feb; 57(1):6-15. PubMed ID: 26935610
[TBL] [Abstract][Full Text] [Related]
19. Mammalian target of rapamycin inhibitor-associated stomatitis in hematopoietic stem cell transplantation patients receiving sirolimus prophylaxis for graft-versus-host disease.
Villa A; Aboalela A; Luskin KA; Cutler CS; Sonis ST; Woo SB; Peterson DE; Treister NS
Biol Blood Marrow Transplant; 2015 Mar; 21(3):503-8. PubMed ID: 25482865
[TBL] [Abstract][Full Text] [Related]
20. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease.
Ilhan O; Arat M; Arslan O; Ayyildiz E; Sanli H; Beksac M; Ozcan M; Gürman G; Akan H
Transfus Apher Sci; 2004 Jun; 30(3):185-7. PubMed ID: 15172621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]